Drugs / favezelimab/pembrolizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04938817 | Aug 2021 → Dec 2029 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | favezelimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04938817 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT04938817 ↗ |